These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33788422)

  • 1. Hemodialysis Clearance of Enarodustat (JTZ-951), an Oral Erythropoiesis Stimulating Agent, in Patients with End-Stage Renal Disease.
    Pai SM; Yamada H
    Clin Pharmacol Drug Dev; 2021 May; 10(5):463-470. PubMed ID: 33788422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Mass Balance Study of
    Pai SM; Connaire J; Yamada H; Enya S; Gerhardt B; Maekawa M; Tanaka H; Koretomo R; Ishikawa T
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):728-741. PubMed ID: 31876104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Enarodustat in Non-Japanese and Japanese Healthy Subjects and in Patients With End-Stage Renal Disease on Hemodialysis.
    Pai SM; Kambhampati SRP; Naruhashi S; Yamada H
    Clin Pharmacol Drug Dev; 2023 Jul; 12(7):683-690. PubMed ID: 37203396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thorough QT/QTc Evaluation of the Cardiac Safety of Enarodustat (JTZ-951), an Oral Erythropoiesis-Stimulating Agent, in Healthy Adults.
    Pai SM; Yamada H; Kleiman RB; Zhuo R; Huang QM; Koretomo R
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):884-898. PubMed ID: 34159762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A highly sensitive and selective UPLC-MS/MS assay for the determination of enarodustat (JTZ-951) in human plasma.
    Pai S; Huang MQ; Maki K; Waldron M; Yoshikawa T; Keller T; Burnett J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1176():122754. PubMed ID: 34052557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
    Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Maeda K; Miyazawa Y; Hirakata H
    Nephron; 2019; 143(2):77-85. PubMed ID: 31117088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
    Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
    Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
    Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enarodustat to treat anemia in chronic kidney disease.
    Fukui K; Tanaka T; Nangaku M
    Drugs Today (Barc); 2021 Aug; 57(8):491-497. PubMed ID: 34405206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
    Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Matsui A; Hirakata H
    Am J Nephrol; 2019; 49(2):165-174. PubMed ID: 30699415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
    Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
    Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies.
    Akizawa T; Nangaku M; Yamaguchi T; Koretomo R; Maeda K; Yamada O; Hirakata H
    Ther Apher Dial; 2022 Apr; 26(2):345-356. PubMed ID: 34390314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.
    Mück W; Park S; Jäger W; Voith B; Wandel E; Galle PR; Schwarting A
    Int J Clin Pharmacol Ther; 2001 May; 39(5):192-8. PubMed ID: 11380064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
    Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
    HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men.
    Singh AB; Norris K; Modi N; Sinha-Hikim I; Shen R; Davidson T; Bhasin S
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2437-45. PubMed ID: 11397836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
    Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T
    Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.
    Fujikawa R; Nagao Y; Fujioka M; Akizawa T
    Ther Apher Dial; 2022 Aug; 26(4):679-693. PubMed ID: 35218616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the Phosphate Binder Sevelamer Carbonate on the Bioavailability of Enarodustat, an Oral Erythropoiesis Stimulating Agent.
    Pai SM; Yamada H
    Clin Pharmacol Drug Dev; 2024 Jan; 13(1):111-116. PubMed ID: 37975611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of hemodialysis on ceftazidime pharmacokinetics.
    Nikolaidis P; Tourkantonis A
    Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis.
    Zomorodi K; Chen D; Lee L; Lasseter K; Marbury T
    J Clin Pharmacol; 2019 Aug; 59(8):1120-1129. PubMed ID: 30865315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.